(19) World Intellectual Property Organization

International Bureau

(43) International Publication Date 1 April 2010 (01.04.2010)





(10) International Publication Number WO 2010/037135 A3

- (51) International Patent Classification: A61K 38/00 (2006.01) C07K 19/00 (2006.01) C07K 14/47 (2006.01)
- (21) International Application Number:

PCT/US2009/058883

(22) International Filing Date:

29 September 2009 (29.09.2009)

(25) Filing Language:

English

(26) Publication Language:

English

US

(30) Priority Data:

61/101,058 29 September 2008 (29.09.2008)

- (71) Applicants (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFOR-NIA [US/US]; 1111 Franklin Street, 5th Floor, Oakland, CA 94607-5200 (US). ROSALIND FRANKLIN UNI-VERSITY OF MEDICINE AND SCIENCE [US/US]; 3333 Green Bay Road, North Chicago, IL 60064 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MASLIAH, Eliezer [US/US]; 4661 Corte Mar Del Corazon, San Diego, CA 92130 (US). SPENCER, Brian [US/US]; 2912 Kalmia Street, San Diego, CA 92104 (US). ROCKENSTEIN, Edward [US/US]; 2026 Terrakappa Avenue, Spring Valley, CA 91977 (US). MARR, Robert [US/US]; 3333 Green Bay Road, North Chicago, IL 60064 (US).

- (74) Agent: EINHORN, Gregory, P.; Gavrilovich, Dodd & Lindsey Llp, 4660 La Jolla Village Drive, Suite 750, San Diego, CA 92122 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

[Continued on next page]

(54) Title: COMPOUNDS FOR REVERSING AND INHIBITING PROTEIN AGGREGATION, AND METHODS FOR MAK-ING AND USING THEM




Figure 2

(57) Abstract: The invention provides compositions for increasing the clearance of protein aggregates, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for accelerating protein aggregate clearance in the CNS, e.g., for treating diseases that are characterized by protein aggregation - including some degenerative neurological diseases such as Parkinson's disease. In one aspect, the compositions of the invention specifically target synuclein, beta-amyloid and/or tau protein aggregates, and the methods of the invention can be used to specifically prevent, reverse, slow or inhibit synuclein, beta-amyloid and/or tau protein aggregation. In alternative embodiments, the compositions and methods of the invention, are used to treat, prevent, reverse (partially or completely) or ameliorate (including slowing the progression of) degenerative neurological diseases related to or caused by protein aggregation, e.g., synuclein, beta-amyloid and/or tau protein aggregation. In one aspect, compositions and methods of this invention are used to treat, prevent or ameliorate (including slowing the progression of) Parkinson's disease, fronto-temporal dementia (FTD), Alzheimer's Disease (AD), Lewy body disease (LBD) and Multiple system atrophy (MSA).







(88) Date of publication of the international search report: $$22\ \mathrm{July}\ 2010$

International application No. **PCT/US2009/058883**

A. CLASSIFICATION OF SUBJECT MATTER

C07K 19/00(2006.01)i, C07K 14/47(2006.01)i, A61K 38/00(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 8: C07K 19/00, C12Q 1/68, G01N 33/53, A61K 38/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) eKOMPASS(KIPO internal)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2005/0170359 A1 (Berislav Zlokovic) 4 August 2005 See the whole document.	1-7, 11, 13, 14
A	US 2005/0239062 A1 (Berislav Zlokovic) 27 October 2005 See the whole document.	1-7, 11, 13, 14
A	US 2004/0038302 A1 (Roger Nitsch et al.) 26 February 2004 See the whole document.	1-7, 11, 13, 14
A	William E. Klunk et al., Imaging Brain Amyloid in Alzheimer's Disease with Pittsburgh Compound-B, Annals of Neurology, 2004, Vol. 55, p306-319 See the whole document.	1-7, 11, 13, 14
A	Angela R. Jones1 and Eric V. Shusta, Blood-Brain Barrier Transport of Therapeutics via Receptor-Mediation, Pharmaceutical Research, 2007, Vol. 24, No. 9, p1759-1771 See the whole document.	1-7, 11, 13, 14

\boxtimes	Further document	s are listed	in the	continuation	of Box C.
-------------	------------------	--------------	--------	--------------	-----------

See patent family annex.

- * Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

international search Date of mailing of the international search report

17 MAY 2010 (17.05.2010) 31 MAY 2010 (31.05.2010)

Name and mailing address of the ISA/KR



Korean Intellectual Property Office Government Complex-Daejeon, 139 Seonsa-ro, Seogu, Daejeon 302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

CHANG, BONG HO

Telephone No. 82-42-481-8289



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2009/058883

Box No. II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This internat	ional search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
bec C th	ims Nos.: 8-10, 12 ause they relate to subject matter not required to be searched by this Authority, namely: laims 8-10 and 12 pertain to methods for treatment of the human body by therapy, and thus relate to a subject matter which e International Searching Authority is not required to search, under Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the egulations under the PCT.
└ bec	ims Nos.: ause they relate to parts of the international application that do not comply with the prescribed requirements to such an ent that no meaningful international search can be carried out, specifically:
	ims Nos.: sause they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No. III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This Internat	ional Searching Authority found multiple inventions in this international application, as follows:
1. As	all required additional search fees were timely paid by the applicant, this international search report covers all searchable ms.
	all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment any additional fee.
	only some of the required additional search fees were timely paid by the applicant, this international search report covers y those claims for which fees were paid, specifically claims Nos.:
	required additional search fees were timely paid by the applicant. Consequently, this international search report is ricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on	Protest The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee. The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2009/058883

ategory*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
A	Shingo Ito et al., Cerebral Clearance of Human Amyloid-beta Peptide (1-40) Across the Blood-brain Barrier is Reduced by Self-aggregation and Formation of Low-density Lipoprotein Receptor-related Protein-1 Ligand Complexes, Journal of Neurochemistry, 2007, Vol.103, p2482-2490 See the whole document.	1-7, 11, 13, 14
A	Laura Morelli et al., The Degradation of Amyloid b As a Therapeutic Strategy in Alzheimer's Disease and Cerebrovascular Amyloidoses, Neurochemical Research, 2002, Vol. 27, No. 11, p1387-1399 See the whole document.	1-7, 11, 13, 14
A	Vincenzo Giordan et al., Systemic and Brain Metabolic Dysfunction As a New Paradigm for Approaching Alzheimer's Dementia, Neurochemical Research, 2007, Vol. 32, p555-567 See the whole document.	1-7, 11, 13, 14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2009/058883

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2005-0170359 A1	04.08.2005	AU 2003-248660 A1	22.12.2003
		AU 2003-248660 A8	22.12.2003
		EP 1532258 A1	25.05.2005
		WO 2003-104466 A1	18.12.2003
US 2005-0239062 A1	27.10.2005	AU 2001-64801 A1	03.12.2001
		AU 2001-264801 A8	03.12.2001
		CA 2408566 A1	29.11.2001
		EP 1290451 A2	12.03.2003
		EP 1290451 B1	07.12.2005
		JP 2004-510957 A	08.04.2004
		US 07695903 B2	13.04.2010
		US 2004-0259159 A1	23.12.2004
		WO 2001-090758 A2	29.11.2001
		WO 2001-090758 A3	29.11.2001
US 2004-038302 A1	26.02.2004	AU 1225702 A	02.04.2002
		US 2006-142194 A1	29.06.2006
		WO 02-25279 A2	28.03.2002
		WO 02-25279 A3	04.07.2002